Potential therapeutics forγ-globin gene induction in the β-thalassemia syndromes.
| Patient Characteristics . | Therapeutic Classes . |
|---|---|
| Abbreviations: EPO, erythropoietin; HDACi, histone deacetylase inhibitor | |
| Thalassemia intermedia Low HbF (< 30%) and Low EPO (< 100 mU/mL) Total Hb > 5 g/dL | • EPO • Fetal globin gene activator |
| Thalassemia intermedia/major High HbF (> 60%) and High EPO (> 160 mU/mL) Total Hb > 4–5 g/dL | • Fetal globin gene activator or • Hydroxyurea |
| Thalassemia major Total Hb > 4–5 g/dL | • EPO • Fetal globin gene activator • Hypomethylating agent/HDACi (?) |
| Patient Characteristics . | Therapeutic Classes . |
|---|---|
| Abbreviations: EPO, erythropoietin; HDACi, histone deacetylase inhibitor | |
| Thalassemia intermedia Low HbF (< 30%) and Low EPO (< 100 mU/mL) Total Hb > 5 g/dL | • EPO • Fetal globin gene activator |
| Thalassemia intermedia/major High HbF (> 60%) and High EPO (> 160 mU/mL) Total Hb > 4–5 g/dL | • Fetal globin gene activator or • Hydroxyurea |
| Thalassemia major Total Hb > 4–5 g/dL | • EPO • Fetal globin gene activator • Hypomethylating agent/HDACi (?) |